GlassScriptPhysician profile
Lev Yagudayev
NPI 1568778314
$26,185.74
in general payments reported to CMS, 2019-2025
28 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,255 · 2022: $3,728 · 2023: $3,099 · 2024: $4,148 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,786 · Travel and Lodging: $5,480 · Consulting Fee: $4,590 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,785.62 |
| Travel and Lodging | $5,480.12 |
| Consulting Fee | $4,590.00 |
| Education | $346.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $8,226.76 | 2025 | Vtama |
| Dermavant Sciences, INC. | $2,821.36 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $2,393.19 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $1,826.19 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $1,701.98 | 2021-2025 | |
| Genzyme Corporation | $1,577.94 | 2021-2025 | |
| Janssen Biotech, INC. | $1,191.26 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $1,004.02 | 2021-2025 | Repatha, Otezla, Otezla |
| Galderma Laboratories, L.P. | $610.52 | 2021-2025 | Nemluvio |
| Pfizer INC. | $584.99 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $486.19 | 2021-2024 | |
| Incyte Corporation | $477.44 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $452.32 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $362.65 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $303.15 | 2021-2023 | Olumiant |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $293.53 | 2022-2025 | Ilumya |
| Ucb, INC. | $289.86 | 2021-2025 | Bimzelx |
| Glaxosmithkline, LLC. | $250.00 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $250.00 | 2022 | |
| Botanix Sb INC | $176.60 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $139.74 | 2023-2024 | |
| Almirall LLC | $138.75 | 2021-2025 | Seysara |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.00 | 2021-2025 | Siliq |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Dermira, INC. | $32.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lev Yagudayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.